PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Pharmaceutical forum is open to any pharmacist who is engaged with industrial practice. Its a platform to share and update your industry related knowledge and skills. Eg: DCGI notifications, D&C Act, Formulation methods and Policy initiatives.
Forum rules: Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
  • User avatar
#2616
1. Rituxan

Company: Roche
2017 U.S. sales: $4.41 billion
Disease: Blood cancers, rheumatoid arthritis
Competition expected: Mid- to end-2018

2. Neulasta

Company: Amgen
2017 U.S. sales: $3.93 billion
Use: White blood cell booster
Competition expected: Mid-2018

3. Lyrica

Company: Pfizer
2017 U.S. sales: $3.46 billion
Disease: Nerve and muscle pain
Patent expiration: Dec. 30

4. Advair

Company: GlaxoSmithKline
2017 U.S. sales: $2.23 billion
Disease: Asthma and COPD
Competition expected: Mid- to end-2018

5. Xolair

Company: Roche/Novartis
2017 U.S. sales: $1.83 billion
Disease: Allergic asthma and chronic idiopathic urticaria
Patent expiration: 2018

6. Epogen/Procrit

Company: Amgen and Johnson & Johnson
2017 U.S. sales: $1.77 billion
Disease: Anemia
Competition expected: Unknown

7. Restasis

Company: Allergan
2017 U.S. sales: $1.41 billion
Disease: Dry eye
Competition expected: Between April and July of 2018

8. Cialis

Company: Eli Lilly
2017 U.S. sales: $1.359 billion
Disease: Erectile dysfunction
Patent expiration: Sept. 27

9. Sensipar

Company: Amgen
2017 U.S. sales: $1.347 billion
Use: Calcium reducer
Patent expiration: March 8

10. Zytiga

Company: Johnson & Johnson
2017 U.S. sales: $1.228 billion
Disease: Prostate cancer
Generics expected: October 2018
Similar Topics
Topics Statistics Last post
0 Replies 
525 Views
by Krishna K
20 Jun 2018, 21:56
APRCET- 2018
by Admin  - 02 Jul 2018, 10:41  - In: Clinical Research & Publication
0 Replies 
427 Views
by Admin
02 Jul 2018, 10:41
PCI - Pharmacist Day Poster 2018
by Admin  - 21 Sep 2018, 17:30  - In: Newsletters & Seminars
0 Replies 
566 Views
by Admin
21 Sep 2018, 17:30
0 Replies 
625 Views
by Admin
04 May 2018, 14:11
0 Replies 
624 Views
by Admin
28 Jun 2018, 08:31

Tags

PharmD Info Online Group Discussion Disc[…]

The Pharmacy Council of India (PCI) has launched a[…]

Indian Association of Colleges of Pharmacy. A/C N[…]

PCI chalks out plans to allay concerns of educatio[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES